Concepedia

Mario Altendorfer

MA

Statistics

Publications

2

Citations

88

H-Index

2

Active since

2016

Affiliations

Boehringer Ingelheim (Germany)(Current)

Christchurch Clinical Studies Trust

Mario Altendorfer is an author at Boehringer Ingelheim (Germany) specializing in pharmacokinetics, pharmacokinetics of monoclonal antibodies, and subjects.

Publications per year

2016–2017

2

Publications

2

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects

Christopher Wynne, Mario Altendorfer, Ivo Sonderegger et al. · Expert Opinion on Investigational Drugs · 2016 · 59 citations · Full text

, , +15

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

Willem Hettema, Christopher Wynne, Benjamin Lang et al. · Expert Opinion on Investigational Drugs · 2017 · 29 citations · Full text

, , +17

1–2 of 2